Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 2
2019 3
2020 4
2021 4
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
PARP inhibition in prostate cancer.
Nientiedt C, Duensing A, Zschäbitz S, Jäger D, Hohenfellner M, Stenzinger A, Duensing S. Nientiedt C, et al. Genes Chromosomes Cancer. 2021 May;60(5):344-351. doi: 10.1002/gcc.22903. Epub 2020 Oct 28. Genes Chromosomes Cancer. 2021. PMID: 33084183 Review.
Revisiting the Role of p53 in Prostate Cancer.
Teroerde M, Nientiedt C, Duensing A, Hohenfellner M, Stenzinger A, Duensing S. Teroerde M, et al. Among authors: nientiedt c. In: Bott SRJ, Ng KL, editors. Prostate Cancer [Internet]. Brisbane (AU): Exon Publications; 2021 May 27. Chapter 8. In: Bott SRJ, Ng KL, editors. Prostate Cancer [Internet]. Brisbane (AU): Exon Publications; 2021 May 27. Chapter 8. PMID: 34181372 Free Books & Documents. Review.
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.
Sauer S, Kriegsmann K, Nientiedt C, Schmitt A, Müller-Tidow C, Raab MS, Kauer J. Sauer S, et al. Among authors: nientiedt c. Transfus Med Hemother. 2023 Mar 24;50(5):371-381. doi: 10.1159/000529691. eCollection 2023 Oct. Transfus Med Hemother. 2023. PMID: 37936633 Free PMC article.
PARP inhibition in BRCA2-mutated prostate cancer.
Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S. Nientiedt C, et al. Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445. Ann Oncol. 2017. PMID: 27687312 Free article. No abstract available.
Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Nientiedt C, Budczies J, Endris V, Kirchner M, Schwab C, Jurcic C, Behnisch R, Hoveida S, Lantwin P, Kaczorowski A, Geisler C, Dieffenbacher S, Falkenbach F, Franke D, Görtz M, Heller M, Himmelsbach R, Pecqueux C, Rath M, Reimold P, Schütz V, Simunovic I, Walter E, Hofer L, Gasch C, Schönberg G, Pursche L, Hatiboglu G, Nyarangi-Dix J, Sültmann H, Zschäbitz S, Koerber SA, Jäger D, Debus J, Duensing A, Schirmacher P, Hohenfellner M, Stenzinger A, Duensing S. Nientiedt C, et al. Urol Oncol. 2022 Jan;40(1):8.e11-8.e18. doi: 10.1016/j.urolonc.2021.06.024. Epub 2021 Jul 26. Urol Oncol. 2022. PMID: 34325986 Free article.
Genomic features of renal cell carcinoma with venous tumor thrombus.
Warsow G, Hübschmann D, Kleinheinz K, Nientiedt C, Heller M, Van Coile L, Tolstov Y, Trennheuser L, Wieczorek K, Pecqueux C, Gasch C, Kuru T, Nyarangi-Dix J, Hatiboglu G, Teber D, Perner S, Stenzinger A, Roth W, Hadaschik B, Pahernik S, Jäger D, Grüllich C, Duensing A, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Duensing S. Warsow G, et al. Among authors: nientiedt c. Sci Rep. 2018 May 10;8(1):7477. doi: 10.1038/s41598-018-25544-z. Sci Rep. 2018. PMID: 29748622 Free PMC article.
Mutations in BRCA2 and taxane resistance in prostate cancer.
Nientiedt C, Heller M, Endris V, Volckmar AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher P, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S. Nientiedt C, et al. Sci Rep. 2017 Jul 4;7(1):4574. doi: 10.1038/s41598-017-04897-x. Sci Rep. 2017. PMID: 28676659 Free PMC article.
The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S. Jenzer M, et al. Among authors: nientiedt c. Cancer Immunol Immunother. 2019 Oct;68(10):1621-1633. doi: 10.1007/s00262-019-02393-x. Epub 2019 Sep 23. Cancer Immunol Immunother. 2019. PMID: 31549213 Free PMC article.
Senescent Tumor Cells Are Frequently Present at the Invasion Front: Implications for Improving Disease Control in Patients with Locally Advanced Prostate Cancer.
Schwarz S, Nientiedt C, Prigge ES, Kaczorowski A, Geisler C, Lucena Porcel C, von Knebel Doeberitz M, Hohenfellner M, Duensing S. Schwarz S, et al. Among authors: nientiedt c. Pathobiology. 2023;90(5):312-321. doi: 10.1159/000530430. Epub 2023 Mar 31. Pathobiology. 2023. PMID: 37004506 Free PMC article.
Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes.
Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, Bruchertseifer F, Kippenberger M, Rathke H, Leichsenring J, Hohenfellner M, Morgenstern A, Haberkorn U, Duensing S, Stenzinger A. Kratochwil C, et al. Among authors: nientiedt c. J Nucl Med. 2020 May;61(5):683-688. doi: 10.2967/jnumed.119.234559. Epub 2019 Oct 10. J Nucl Med. 2020. PMID: 31601699 Free article.
16 results